Biogen promotes Paul McKenzie to executive vice president
pharmafile | June 23, 2016 | Appointment | |
Biogen (Nasdaq: BIIB) has promoted Paul McKenzie to the role of executive vice president for pharmaceutical operations & technology, effective July 1, 2016.
He will report to chief executive George Scangos and earlier served as senior vice president of global biologics manufacturing and technical operations. He replaces John Cox, who last month was named chief executive officer of a new Biogen spin-off company dedicated to advancing treatments for hemophilia.
McKenzie will lead the organization responsible for asset management, technical development, global manufacturing, supply chain operations, quality, and engineering.
He will also oversee construction and operation of Biogen’s advanced biologics manufacturing facility in Solothurn, Switzerland.
Scangos, said: “With his extensive technical and development expertise, we believe Paul is ideally suited to lead the next phase of growth across Biogen’s development and manufacturing operations.”
McKenzie joined Biogen in February from Johnson & Johnson (NYSE: JNJ).






